Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ALLO Allogene Therapeutics
7.720+0.050+0.65%
Close
02/07 16:00 ET
High
7.760
Open
7.670
Turnover
6.69M
Low
7.480
Pre Close
7.670
Volume
874.41K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
'Allogene Therapeutics Evaluation Of Lymphodepletion With ALLO-647 In Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy' - Clinical Trials
'Allogene Therapeutics Evaluation Of Lymphodepletion With ALLO-647 In Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy' - Clinical Trials
Here Are the 10 Most Shorted Stocks on Wall Street
Allogene Therapeutics Presents Preclinical Dagger Platform Technology Data
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
WYNN, MLCO and ALLO Are Among After Hour Movers
Allogene Announces Publication of Preclinical Study on DLL3, AlloCAR T
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) --
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. On
Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock?
Allogene Therapeutics (NASDAQ:ALLO) Upgraded by JPMorgan Chase & Co. to Overweight
JPMorgan Chase & Co. upgraded shares of Allogene Therapeutics (NASDAQ:ALLO – Get Rating) from a neutral rating to an overweight rating in a research report released on Tuesday morning, MarketBeat Rat
Company Overview
More
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
CEO： Dr. David D. Chang, M.D.,PhD
Market： NASDAQ
Listing Date： 10/11/2018
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet